Literature DB >> 17826066

Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up.

Tina J Hieken1, John Cheregi, Miguel Farolan, Joan Kim, Josè M Velasco.   

Abstract

BACKGROUND: The incidence of ductal carcinoma in situ (DCIS) of the breast is increasing. Optimal treatment remains controversial and, because of a long natural history, may not be evident for many years. We undertook this study to identify markers of disease recurrence.
METHODS: We studied 131 pure DCIS patients with a 100-month mean follow-up. We performed a complete histologic review, immunohistochemical staining for p53 and vascular endothelial growth factor expression, and enumerated microvessel density/mm2 using factor VIII-Ab. Statistical analysis was performed by using an SAS software package (Cary, NC).
RESULTS: Eleven patients (8%) developed ipsilateral recurrence at a mean of 55 months (11-137 months) after initial treatment. Three were DCIS, and 8 were invasive cancer. Recurrence was significantly predicted by p53 overexpression (in 55% of tumors that recurred versus 22% of those that did not, P = .02) but not other factors.
CONCLUSIONS: These data suggest that biologic factors may have an important role in predicting recurrence in DCIS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826066     DOI: 10.1016/j.amjsurg.2007.07.002

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  4 in total

1.  Comparative analysis of loss of heterozygosity and expression profile in normal tissue, DCIS and invasive breast cancer.

Authors:  Michal Zikan; Jan Bohm; David Pavlista; David Cibula
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

2.  Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Authors:  Edgar S Díaz-Cruz; Priscilla A Furth
Journal:  Cancer Res       Date:  2010-05-15       Impact factor: 12.701

Review 3.  DNA methylation in ductal carcinoma in situ of the breast.

Authors:  Jia-Min B Pang; Alexander Dobrovic; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2013-06-28       Impact factor: 6.466

4.  Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.

Authors:  Laura G Estévez; Ana Suarez-Gauthier; Elena García; Cristina Miró; Isabel Calvo; María Fernández-Abad; Mercedes Herrero; Manuel Marcos; Cristina Márquez; Fernando Lopez Ríos; Sofía Perea; Manuel Hidalgo
Journal:  Breast Cancer Res       Date:  2014-09-04       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.